Therapeutic monoclonal antibodies may benefit serious infections with Omicron variants of SARS-CoV-2

Omicron variants of SARS-CoV-2 possess the capacity to escape the protective immunity developed by natural infection or vaccination. Therefore, from the therapeutic point, Prof. Jagadeesh Bayry in collaboration with Dr. Suprabhat Mukherjee from Kazi Nazrul University, Asansol investigated the efficiency of 12 therapeutic monoclonal antibodies targeting the RBD region of the spike glycoprotein against all the Omicron variants bearing a mutation in spike protein through molecular docking and molecular dynamics simulation. Their in silico evidence revealed that adintivimab, beludivimab, and regadanivimab are the most potent monoclonal antibodies to form strong biophysical interactions and neutralize most of the Omicron variants.

Link to the full text of the article: https://www.mdpi.com/2073-4468/12/1/17